PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

Clinical trial NCT06639607 · SUSPENDED

Trial details

NCT number: NCT06639607
Sponsor: Washington University School of Medicine
Status: SUSPENDED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Diffuse Midline Glioma Diffuse Midline High-grade Glioma Medulloblastoma Ependymoma

Start date: 2026-08-31
Primary completion: 2031-08-31
Enrollment: 68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.